Newly contaminated COVID-19 sufferers have two new therapy choices that may be taken at dwelling.
However that comfort comes with a catch: The capsules need to be taken as quickly as attainable as soon as signs seem.
The problem is getting examined, getting a prescription and beginning the capsules in a brief window.
Learn extra:
Canada secures orders of Merck, Pfizer COVID-19 antiviral capsules
U.S. regulators licensed Pfizer’s tablet, Paxlovid, and Merck’s molnupiravir this week.
In high-risk sufferers, each have been proven to scale back the possibilities of hospitalization or demise from COVID-19, though Pfizer’s was rather more efficient.
Right here’s a more in-depth look:
Who ought to take these capsules?
The antiviral capsules aren’t for everybody who will get a optimistic check. The capsules are meant for these with gentle or average COVID-19 who usually tend to turn into critically in poor health.
That features older folks and people with different well being circumstances like coronary heart illness, most cancers or diabetes that make them extra weak. Each capsules have been OK’d for adults whereas Paxlovid is permitted for youngsters ages 12 and older.
Who should not take these capsules?
Merck’s molnupiravir will not be licensed for youngsters as a result of it’d intrude with bone progress. It additionally isn’t beneficial for pregnant ladies due to the potential for beginning defects. Pfizer’s tablet isn’t beneficial for sufferers with extreme kidney or liver issues. It additionally is probably not the best choice for some as a result of it could work together with different prescriptions a affected person is taking. The antiviral capsules aren’t licensed for folks hospitalized with COVID-19.
What is the therapy window?
The capsules need to be began as quickly as attainable, inside 5 days of the beginning of signs. Cough, headache, fever, the lack of style or scent and muscle and physique aches are among the many extra frequent indicators. The Facilities for Illness Management and Prevention affords an internet site to verify your signs.
Dr. Cameron Wolfe, an infectious illness specialist at Duke College Hospital, advises getting a check as quickly as you may have signs of COVID-19.
“For those who wait till you may have began to get breathless, you may have already to a big extent missed the window the place these medication shall be useful,” Wolfe stated.
The place can I get the capsules?
You’ll want a prescription first from a health care provider or different licensed well being employee.
The U.S. authorities is shopping for the capsules from Merck and Pfizer and offering them at no cost, however provides shall be restricted initially.
Learn extra:
Merck to make its COVID-19 antiviral tablet in Canada, firm publicizes
They’ll be shipped to states the place they are going to be out there at drugstores, neighborhood well being facilities and different locations. Therapy lasts 5 days.
Some pharmacists might be able to administer a fast COVID-19 check and prescribe the capsules multi function go to. They already do that in lots of states for flu or strep throat.
Will the capsules work for the Omicron variant?
The capsules are anticipated to be efficient towards omicron as a result of they don’t goal the spike protein the place many of the variant’s worrisome mutations reside.
The 2 capsules work in numerous methods to forestall the virus from reproducing.
Are there different choices for brand spanking new COVID-19 sufferers?
Sure, however they aren’t as simple to make use of as a tablet: They’re given by IV or injection, usually at a hospital or clinic.
Three medication present virus-fighting antibodies, though laboratory testing suggests the 2 aren’t efficient towards Omicron.
Learn extra:
Commonplace medication used to battle COVID-19 might not work towards Omicron: U.S. docs
British drugmaker GlaxoSmithKline’s antibody drug seems to work, and officers say they’re working to extend the U.S. provide.
The one antiviral drug accredited within the U.S., remdesivir, is for folks hospitalized with COVID-19.
— AP Well being Author Matthew Perrone contributed to this report.
View hyperlink »
© 2021 The Canadian Press